As previously reported, BofA analyst Joshua Dennerlein upgraded Sabra Health Care to Neutral from Underperform with a price target of $14, up from $11. The firm’s upgrade reflects upside from a recovery in senior housing as well as management’s “new found disciplined approach to external growth” and the stock’s relative valuation compared to peers, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SBRA:
